The head and neck cancer drugs market comprises drugs that are used for treating various types of cancers that develop in the head and neck regions such as oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx. The increasing prevalence of head and neck cancers, rising uptake of targeted therapies, and growing pipeline of novel therapeutic molecules are the key factors driving the growth of the market. Head and neck cancers are the sixth most prevalent cancers globally. According to GLOBOCAN 2020, there were about 933,309 new cases of head and neck cancers reported worldwide in 2020. Chemotherapy drugs and targeted therapy drugs are commonly used to treat head and neck cancers.
The Global head and neck cancer drugs market is estimated to be valued at US$ 2288.22 Bn in 2024 and is expected to exhibit a CAGR of 8.2% over the forecast period 2024 to 2030.
Key players operating in the Head and Neck Cancer Drugs are Johnson & Johnson Services, Inc. (DePuy Synthes), Double Medical Technology Inc., Orthofix Holdings, Inc., Ortho-SUV Ltd., Response Ortho LLC, Smith & Nephew, Stryker Corporation , Zimmer Biomet, Auxein Medical, Acumed, Tasarimmed Tıbbi Mamuller San. Tic A.Ş., Orthopaedic Implant Company (€œOIC€), Gexfix SA, WishBone Medical, Inc., and Matrix Meditech.
The key players are focusing on improving their product pipeline through strategic collaboration and acquisition activities. Some of the key opportunities in the head and neck cancer drugs market include rising focus on developing novel combination therapies, precision medicine approaches and targeted therapies. Geographically, North America dominates the global head and neck cancer drugs market followed by Europe. However, Asia Pacific region is expected to witness high growth owing to increasing healthcare expenditure and rising awareness about head and neck cancers in the region.
Key players operating in the Head And Neck Cancer Drugs Market are focusing on expanding their presence in emerging markets such as Asia Pacific, Middle East and Latin America. For instance, in 2021, Johnson & Johnson opened a new manufacturing facility in Singapore to support the demand for pharmaceuticals in Asia Pacific region. Similarly, Double Medical Technology Inc. in 2021 expanded its sales network in 20 key markets across Latin America and Asia to strengthen its global foothold.
- Increasing incidence of head and neck cancers globally is a major factor driving the growth of head and neck cancer drugs market. According to WHO, head and neck cancers are the sixth most common cancers globally with over 900,000 new cases reported annually.
- Strong pipeline of drugs for treatment of head and neck cancers. Several pharmaceutical companies are focusing on developing innovative therapies for treatment of recurrent/metastatic head and neck cancers which is supporting the market growth.
- Low success rate of drug development and high attrition rates pose significant challenge for pharmaceutical companies in this market. Only a small fraction of candidates entering clinical trials gets approved which increases R&D costs.
- High cost of targeted therapies for head and neck cancers limits their uptake in developing nations. Many biologic and targeted therapies used for treatment cost over $10,000 annually which is unaffordable for patients in low and middle-income countries.
The head and neck cancer drugs market is dominated by the squamous cell carcinoma sub segment. Squamous cell carcinoma accounts for over 90% of all head and neck cancers. This cancer type arises from the squamous cells that line the moist, mucosal surfaces inside the head and neck such as the lips, mouth, throat, vocal cords, or part of the esophagus, windpipe, and the sinuses. Early detection is crucial as squamous cell carcinoma often has few symptoms in the initial stages and can spread quickly if left untreated. The majority of treatments include chemotherapy, radiation therapy or surgery depending on the stage and location of cancer. Targeted therapies for squamous cell carcinoma include cetuximab and pembrolizumab.
On a regional basis, North America is expected to dominate the head and neck cancer drugs market during the forecast period. High incidence of head and neck cancer along with early diagnosis and availability of advanced treatment options in the region is driving market growth. Asia Pacific is predicted to be the fastest growing market owing to large patient population, increasing awareness, growing healthcare expenditure in emerging economies such as India and China. These countries are also anticipated to emerge as important hubs for clinical trials and development of biosimilars. Europe holds a significant share due to high adoption of premium priced novel drug therapies and targeted cancer therapies in countries like Germany, UK and France. Latin America and Middle East & Africa present lucrative opportunities for market players but affordability and lack of awareness could hamper market growth to some extent in these regions.
Get more insights on this topic: